<p>Metavia Inc., a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced positive results from its ongoing collaboration with Syntekabio, Inc., an AI-driven drug discovery company. The partnership leverages Syntekabio’s proprietary DeepMatcher® platform to confirm key therapeutic targets for Metavia’s candidate Vanoglipel. The AI-modeling results demonstrated strong inflammatory and cardiometabolic target engagement, supporting the further development of Vanoglipel for conditions such as MASH and potentially type 2 diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77714) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

TECH

SBIO

Reuters

Proshares Ultra Nasdaq Biotech

Bio-Techne

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

MetaVia

Invesco Biotechnology & Genome ETF

Cytek Biosciences

SPDR S&P Health Equip

VG Health

iShares Global Healthcare

Telesis Bio

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Metavia Collaborates with Syntekabio on AI-Driven Drug Discovery